ENAMEX ID="NYU_ENAMEX494" TYPE="ORGANIZATION" START="93" END="114" TEXT="evidence review group"
ENAMEX ID="NYU_ENAMEX493" TYPE="ORGANIZATION" START="116" END="119" TEXT="ERG"
RELATION ID="NYU_RELATION495" TYPE="ABBREVIATE" START="93" END="119" ARG1="NYU_ENAMEX494" ARG1_NAME="FULLNAME" ARG2="NYU_ENAMEX493" ARG2_NAME="SHORTNAME" ARG1_TEXT="evidence review group" ARG2_TEXT="ERG" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON497" START="574" END="619" TEXT="pegylated liposomal doxorubicin hydrochloride"
JARGON ID="NYU_JARGON496" START="621" END="625" TEXT="PLDH"
RELATION ID="NYU_RELATION498" TYPE="ABBREVIATE" START="574" END="625" ARG1="NYU_JARGON497" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON496" ARG2_NAME="SHORTNAME" ARG1_TEXT="pegylated liposomal doxorubicin hydrochloride" ARG2_TEXT="PLDH" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON500" START="753" END="780" TEXT="randomised controlled trial"
JARGON ID="NYU_JARGON499" START="782" END="785" TEXT="RCT"
RELATION ID="NYU_RELATION501" TYPE="ABBREVIATE" START="753" END="785" ARG1="NYU_JARGON500" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON499" ARG2_NAME="SHORTNAME" ARG1_TEXT="randomised controlled trial" ARG2_TEXT="RCT" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON503" START="1314" END="1340" TEXT="quality-adjusted-life-year"
JARGON ID="NYU_JARGON502" START="1342" END="1346" TEXT="QALY"
RELATION ID="NYU_RELATION504" TYPE="ABBREVIATE" START="1314" END="1346" ARG1="NYU_JARGON503" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON502" ARG2_NAME="SHORTNAME" ARG1_TEXT="quality-adjusted-life-year" ARG2_TEXT="QALY" GRAM_SIGNAL="PARENTHESES"
JARGON ID="NYU_JARGON506" START="1358" END="1384" TEXT="mixed treatment comparison"
JARGON ID="NYU_JARGON505" START="1386" END="1389" TEXT="MTC"
RELATION ID="NYU_RELATION507" TYPE="ABBREVIATE" START="1358" END="1389" ARG1="NYU_JARGON506" ARG1_NAME="FULLNAME" ARG2="NYU_JARGON505" ARG2_NAME="SHORTNAME" ARG1_TEXT="mixed treatment comparison" ARG2_TEXT="MTC" GRAM_SIGNAL="PARENTHESES"
